JP4841054B2 - 新規インスリン／ｉｇｆ／リラキシンファミリーポリペプチドおよびそのｄｎａ - Google Patents

新規インスリン／ｉｇｆ／リラキシンファミリーポリペプチドおよびそのｄｎａ Download PDF

Info

Publication number
JP4841054B2
JP4841054B2 JP2001123210A JP2001123210A JP4841054B2 JP 4841054 B2 JP4841054 B2 JP 4841054B2 JP 2001123210 A JP2001123210 A JP 2001123210A JP 2001123210 A JP2001123210 A JP 2001123210A JP 4841054 B2 JP4841054 B2 JP 4841054B2
Authority
JP
Japan
Prior art keywords
polypeptide
dna
seq
present
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001123210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002345468A5 (https=
JP2002345468A (ja
Inventor
康明 伊藤
伸宏 鈴木
一紀 西
秀樹 木澤
征隆 原田
和宏 大儀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to JP2001123210A priority Critical patent/JP4841054B2/ja
Publication of JP2002345468A publication Critical patent/JP2002345468A/ja
Publication of JP2002345468A5 publication Critical patent/JP2002345468A5/ja
Application granted granted Critical
Publication of JP4841054B2 publication Critical patent/JP4841054B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
JP2001123210A 2000-04-21 2001-04-20 新規インスリン／ｉｇｆ／リラキシンファミリーポリペプチドおよびそのｄｎａ Expired - Fee Related JP4841054B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001123210A JP4841054B2 (ja) 2000-04-21 2001-04-20 新規インスリン／ｉｇｆ／リラキシンファミリーポリペプチドおよびそのｄｎａ

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
JP2000126340 2000-04-21
JP2000126340 2000-04-21
JP2000-126340 2000-04-21
JP2000-205587 2000-07-03
JP2000205587 2000-07-03
JP2000205587 2000-07-03
JP2000247962 2000-08-10
JP2000-247962 2000-08-10
JP2000247962 2000-08-10
JP2000-395050 2000-12-22
JP2000395050 2000-12-22
JP2000395050 2000-12-22
JP2001123210A JP4841054B2 (ja) 2000-04-21 2001-04-20 新規インスリン／ｉｇｆ／リラキシンファミリーポリペプチドおよびそのｄｎａ

Publications (3)

Publication Number Publication Date
JP2002345468A JP2002345468A (ja) 2002-12-03
JP2002345468A5 JP2002345468A5 (https=) 2008-05-29
JP4841054B2 true JP4841054B2 (ja) 2011-12-21

Family

ID=27481250

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001123210A Expired - Fee Related JP4841054B2 (ja) 2000-04-21 2001-04-20 新規インスリン／ｉｇｆ／リラキシンファミリーポリペプチドおよびそのｄｎａ

Country Status (8)

Country Link
US (2) US7049403B2 (https=)
EP (1) EP1283260A4 (https=)
JP (1) JP4841054B2 (https=)
KR (1) KR20020093053A (https=)
CN (1) CN1633498A (https=)
AU (2) AU2001248809B2 (https=)
CA (1) CA2406855A1 (https=)
WO (1) WO2001081562A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9261901A (en) * 2000-09-13 2002-03-26 Smithkline Beecham Corp Novel compounds
AUPR814401A0 (en) * 2001-10-08 2001-11-01 Howard Florey Institute Of Experimental Physiology And Medicine Human 3 relaxin
JP2007524371A (ja) * 2003-03-04 2007-08-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ レラキシン３−ｇｐｃｒ１３５複合体ならびにそれらの生産及び使用
US7638490B2 (en) 2004-02-09 2009-12-29 Eisai R&D Managment Co., Ltd. Methods of affecting feeding and weight in mammals by administration of relaxin-3
EP1789452B1 (en) * 2004-08-25 2012-04-25 Janssen Pharmaceutica NV Relaxin-chimeric polypeptides and their preparation and use
EP2129359B1 (en) * 2007-01-30 2012-03-14 Janssen Pharmaceutica, N.V. Chimeric peptide antagonist for gpcr135 or gpcr142
US20100161366A1 (en) * 2008-12-19 2010-06-24 Achim Clemens Product requirement specification in production model
US9767495B2 (en) * 2008-12-19 2017-09-19 Sap Se Different sales and planning product options
CN116773828B (zh) 2023-08-21 2023-10-31 成都大熊猫繁育研究基地 一种大熊猫rln3酶联免疫检测方法及单克隆抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990013659A1 (en) * 1989-05-04 1990-11-15 Genentech, Inc. Processes and compositions for the isolation of human relaxin
WO2000021996A2 (en) * 1998-10-13 2000-04-20 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
JP2001517444A (ja) * 1997-09-24 2001-10-09 ジェネンテック・インコーポレーテッド インスリン様ポリペプチドとその使用
KR100529270B1 (ko) 1998-12-01 2005-11-21 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
WO2000047776A2 (en) * 1999-02-12 2000-08-17 Zymogenetics, Inc. Insulin-family homolog localized to chromosome 1
US20020012967A1 (en) * 2000-03-10 2002-01-31 Holloway James L. Insulin homolog polypeptide zins4
AU2001236817A1 (en) * 2000-03-10 2001-09-24 Zymogenetics Inc. Insulin homolog polypeptide zins4
AU9261901A (en) 2000-09-13 2002-03-26 Smithkline Beecham Corp Novel compounds

Also Published As

Publication number Publication date
EP1283260A1 (en) 2003-02-12
EP1283260A4 (en) 2004-08-18
KR20020093053A (ko) 2002-12-12
US7410641B2 (en) 2008-08-12
US20060073567A1 (en) 2006-04-06
CN1633498A (zh) 2005-06-29
WO2001081562A1 (en) 2001-11-01
CA2406855A1 (en) 2001-11-01
AU2001248809B2 (en) 2005-05-19
AU4880901A (en) 2001-11-07
US20030158381A1 (en) 2003-08-21
JP2002345468A (ja) 2002-12-03
US7049403B2 (en) 2006-05-23

Similar Documents

Publication Publication Date Title
JP4841054B2 (ja) 新規インスリン／ｉｇｆ／リラキシンファミリーポリペプチドおよびそのｄｎａ
US7833972B2 (en) Proteins and use thereof
KR20020026465A (ko) 신규 폴리펩티드 및 그의 ｄｎａ
WO2001046415A1 (en) Novel tachykinin-like polypeptides and use thereof
EP1179540A1 (en) Novel polypeptide
JP2004073182A (ja) インスリン抵抗性改善剤
JP4344408B2 (ja) 新規タンパク質およびそのｄｎａ
JP4579378B2 (ja) 新規ポリペプチドおよびそのｄｎａ
JP4169651B2 (ja) 新規蛋白質およびその用途
JP4320151B2 (ja) 新規ポリペプチドおよびその用途
JP4761812B2 (ja) マスクリン受容体およびその用途
JP4128030B2 (ja) 新規リガンドおよびそのｄｎａ
JP4676608B2 (ja) 新規タヒキニン様ポリペプチドおよびその用途
JP4300008B2 (ja) 新規タンパク質およびそのｄｎａ
US20090227501A1 (en) Agents for preventing and/or treating upper digestive tract disorders
JP2001149083A (ja) 新規ポリペプチドおよびそのｄｎａ
JP2004026692A (ja) Ｍｅｐｅの新規用途
JP2001299362A (ja) 新規ポリペプチドおよびそのｄｎａ
JP2001299364A (ja) 新規タンパク質およびそのｄｎａ
JP2002335973A (ja) 新規タンパク質およびそのｄｎａ
JP2004166699A (ja) 抗利尿剤
JP2005151826A (ja) Ｃ１ｑｔｎｆ５の用途
JPWO2000014226A1 (ja) 新規タンパク質およびその製造法
JP2004041003A (ja) 新規タンパク質、そのｄｎａおよびその用途
JPWO2001002564A1 (ja) 新規ポリペプチドおよびそのｄｎａ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110906

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111004

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141014

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees